CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioDelivery Sciences International, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioDelivery Sciences International, Inc.
4131 Parklake Ave Ste 225
Phone: (919) 582-9050p:919 582-9050 RALEIGH, NC  27612-2390  United States Fax: (919) 582-9051f:919 582-9051
This company was Merged or Acquired on 3/22/2022.
This company ceased filing statements with the SEC on 4/1/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202112/31/2021YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Peter S.Greenleaf 51 5/1/2018 5/1/2018
President, Chief Commercial Officer Scott M.Plesha 56 10/29/2018 8/1/2015
Chief Executive Officer, Director Jeffrey A.Bailey 59 11/4/2020 3/1/2020
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Arius Pharmaceuticals, Inc.
Arius Two, Inc.
BDSI

General Information
Number of Employees: 200 (As of 3/7/2022)
Outstanding Shares: 103,228,796 (As of 3/7/2022)
Shareholders: 133
Stock Exchange: NASD
Federal Tax Id: 352089858
Fax Number: (919) 582-9051
Email Address: questions@biodeliverysciences.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 1, 2024